Literature DB >> 1747294

von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

J H Jansson1, T K Nilsson, O Johnson.   

Abstract

OBJECTIVE: To evaluate as predictors of reinfarction and mortality tissue plasminogen activator antigen and activity before and after venous occlusion, plasminogen activator inhibitor, von Willebrand factor, and established risk factors.
DESIGN: Prospective study with a mean observation time of 4.9 years.
SETTING: Secondary referral centre, the Department of Internal Medicine, University Hospital of Umeå. PATIENTS: 123 consecutive survivors of myocardial infarction under the age of 70 years. MAIN OUTCOME MEASURES: Reinfarction and deaths from all causes.
RESULTS: 23 patients died and 36 patients had at least one reinfarction. High concentrations of von Willebrand factor were independently associated with both reinfarction and mortality. A history of angina at entry into the study was also independently associated with reinfarction and mortality. Hypertension was independently associated with mortality but not with reinfarction. None of the fibrinolytic or lipid variables was associated with reinfarction or death.
CONCLUSION: A high concentration of von Willebrand factor was a novel index of increased risk for reinfarction and mortality in survivors of myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1747294      PMCID: PMC1024772          DOI: 10.1136/hrt.66.5.351

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  25 in total

1.  Correlation between plasma levels of growth factors and von Willebrand factor.

Authors:  J Nilsson; G Elgue; M Wallin; A Hamsten; M Blombck
Journal:  Thromb Res       Date:  1989-04-15       Impact factor: 3.944

2.  Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA).

Authors:  W Kirschstein; S Simianer; C E Dempfle; H Keller; B Stegaru; P Rentrop; D L Heene
Journal:  Thromb Haemost       Date:  1989-09-29       Impact factor: 5.249

3.  Haemostatic function in myocardial infarction.

Authors:  A Hamsten; M Blombäck; B Wiman; J Svensson; A Szamosi; U de Faire; L Mettinger
Journal:  Br Heart J       Date:  1986-01

4.  Haemostatic variables and the outcome of myocardial infarction.

Authors:  A P Haines; D Howarth; W R North; E Goldenberg; Y Stirling; T W Meade; E B Raftery; M W Millar Craig
Journal:  Thromb Haemost       Date:  1983-12-30       Impact factor: 5.249

5.  IgM lambda globular cytoplasmic inclusions in chronic lymphocytic leukaemia resembling immunocytoma.

Authors:  A Berrebi; M Talmor; E Vorst; P Resnitzky; M Shtalrid
Journal:  Scand J Haematol       Date:  1983-01

6.  Letter: Factor-VIII complex and endothelial damage.

Authors:  B Boneu; M Abbal; J Plante; R Bierme
Journal:  Lancet       Date:  1975-06-28       Impact factor: 79.321

7.  Synthesis of von Willebrand factor by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

8.  Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris.

Authors:  J H Jansson; T K Nilsson; B O Olofsson
Journal:  Eur Heart J       Date:  1991-02       Impact factor: 29.983

9.  Biosynthesis of von Willebrand protein by human megakaryocytes.

Authors:  L A Sporn; S I Chavin; V J Marder; D D Wagner
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

10.  Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease.

Authors:  T B Wahlberg; M Blombäck; I Overmark
Journal:  Acta Med Scand       Date:  1980
View more
  37 in total

1.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

Authors:  A D Blann; M Porter; C N McCollum
Journal:  Br Heart J       Date:  1992-12

2.  Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials.

Authors:  G V Robinson; J C T Pepperell; H C Segal; R J O Davies; J R Stradling
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

3.  Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.

Authors:  A Uddhammar; S Rantapåå-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

4.  The effect of preoperative aspirin administration on postoperative level of von Willebrand factor in off-pump coronary artery bypass surgery.

Authors:  Kaoru Matsuura; Mizuho Imamaki; Atsushi Ishida; Hitoshi Shimura; Masaru Miyazaki
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

5.  Hypercoagulability and haemodynamic abnormalities in atrial fibrillation.

Authors:  G Y Lip
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

Review 6.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

7.  Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function.

Authors:  M E Plater; I Ford; M T Dent; F E Preston; J D Ward
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

8.  Haemostatic Parameters in Patients with Behçet's Disease.

Authors:  Juma K Alkaabi; David Gravell; Hamood Al-Haddabi; Anil Pathare
Journal:  Sultan Qaboos Univ Med J       Date:  2014-04-07

9.  Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation.

Authors:  Manabu Horii; Shiro Uemura; Masahito Uemura; Masanori Matsumoto; Hiromichi Ishizashi; Keiichi Imagawa; Hajime Iwama; Yukiji Takeda; Hiroyuki Kawata; Tamio Nakajima; Yoshihiro Fujimura; Yoshihiko Saito
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

10.  Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patients.

Authors:  Thomas W Jax; Ansgar J Peters; Gunnar Plehn; Frank-Chris Schoebel
Journal:  Cardiovasc Diabetol       Date:  2009-09-07       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.